In the following video, Motley Fool health-care bureau chief Brenton Flynn discusses some diverging trends in the prices of pharmaceuticals. According to Express Scripts' (ESRX) drug trend report, while traditional drug prices are down year over year, prices of specialty drugs have shot up almost 20%. These types of drug are typically more complicated to administer, difficult to discover or manufacture, and generally used for chronic or long-term conditions with few other options. Brenton tells investors why companies continue to shift its focus toward the lucrative specialty drug field.
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
This Report Explains a Key Pharmaceuticals Trend
NASDAQ: ESRX
Express Scripts Holding Company

Why specialty drug prices are soaring.
Brenton Flynn has no position in any stocks mentioned. The Motley Fool recommends Express Scripts. The Motley Fool owns shares of Express Scripts. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned




*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles





Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.